167 related articles for article (PubMed ID: 36992402)
21. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.
Guisado-Vasco P; Carralón-González MM; Aguareles-Gorines J; Martí-Ballesteros EM; Sánchez-Manzano MD; Carnevali-Ruiz D; García-Coca M; Barrena-Puertas R; de Viedma RG; Luque-Pinilla JM; Sotres-Fernandez G; Fernández-Sousa JM; Luepke-Estefan XE; López-Martín JA; Jimeno JM
J Hematol Oncol; 2022 Jan; 15(1):4. PubMed ID: 35012608
[TBL] [Abstract][Full Text] [Related]
22. Migratory Pneumonia in Prolonged SARS-CoV-2 Infection in Patients Treated With B-cell Depletion Therapies for B-cell Lymphoma.
Lee J; Lee R; Beck KS; Han DH; Min GJ; Chang S; Jung JI; Lee DG
Korean J Radiol; 2023 Apr; 24(4):362-370. PubMed ID: 36907590
[TBL] [Abstract][Full Text] [Related]
23. Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19).
Malsy J; Veletzky L; Heide J; Hennigs A; Gil-Ibanez I; Stein A; Lütgehetmann M; Rosien U; Jasper D; Peine S; Hiller J; Haag F; Schmiedel S; Huber S; Jordan S; Addo MM; Schulze Zur Wiesch J
Clin Infect Dis; 2021 Dec; 73(11):e4020-e4024. PubMed ID: 33103195
[TBL] [Abstract][Full Text] [Related]
24. The rate of SARS-CoV-2 among asymptomatic non-immunised low-risk parturient women between the two waves.
Al-Hussaini TK; EzzEldin AM; Shaaban OM; Abdel-Aleem MA; Kamal DT; Ibrahim MN
J Obstet Gynaecol; 2022 Aug; 42(6):1868-1873. PubMed ID: 35484953
[TBL] [Abstract][Full Text] [Related]
25. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Steroid Treatment for SARS-CoV-2 Pneumonia With Cryptogenic Organizing Pneumonia-Like Reaction: A Case Report.
Kim T; Son E; Jeon D; Lee SJ; Lim S; Cho WH
Disaster Med Public Health Prep; 2022 Apr; 16(2):491-494. PubMed ID: 33100248
[TBL] [Abstract][Full Text] [Related]
27. Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: A case report and literature overview.
Xiao F; Wan P; Wei Q; Wei G; Yu Y
J Med Virol; 2022 Jul; 94(7):3133-3137. PubMed ID: 35274321
[TBL] [Abstract][Full Text] [Related]
28. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
Heger JM; Eichenauer DA; Kasper P; Böll B; Shimabukuro-Vornhagen A; Kochanek M
Eur J Haematol; 2019 Sep; 103(3):268-271. PubMed ID: 31211882
[TBL] [Abstract][Full Text] [Related]
29. Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
Steffanoni S; Calimeri T; Laurenge A; Fox CP; Soussain C; Grommes C; Tisi MC; Boot J; Crosbie N; Visco C; Arcaini L; Chaganti S; Sassone MC; Alencar A; Armiento D; Romano I; Dietrich J; Itchaki G; Bruna R; Fracchiolla NS; Arletti L; Venditti A; Booth S; Musto P; Hoang Xuan K; Batchelor TT; Cwynarski K; Ferreri AJM
Br J Haematol; 2022 Nov; 199(4):507-519. PubMed ID: 35945164
[TBL] [Abstract][Full Text] [Related]
30. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
[TBL] [Abstract][Full Text] [Related]
31. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
32. Extracorporeal Membrane Oxygenation for Secondary Organizing Pneumonia after Severe SARS-CoV-2 Infection: A Case Report.
Kimura T; Onitsuka C; Kawahara T; Fukuda Y; Homma T; Watanabe T; Ohsugi K; Ichikawa Y; Shono A; Kotani T; Sagara H
Medicina (Kaunas); 2021 Sep; 57(10):. PubMed ID: 34684050
[TBL] [Abstract][Full Text] [Related]
33. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
34. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
35. Acute Generalized Exanthematous Pustulosis (AGEP) in 12 Patients Treated for SARS-CoV-2 Positive Pneumonia.
Pezzarossa E; Ungari M; Caresana G; Sagradi F; Cimardi L; Pan A; Testa S; Aguggini S; Varotti E; Tanzi G; Manotti L; Ferrero G; Gusolfino MD; Trombatore M;
Am J Dermatopathol; 2021 May; 43(5):342-348. PubMed ID: 33405402
[TBL] [Abstract][Full Text] [Related]
36. Highlighted Prospects of an IgM/IgG Antibodies Test in Identifying Individuals With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
Li Y; He Q; Yu R; Jiang H; Wang W; Feng D; Hou G; Zhou H; Jiang Y; Xiang Z
Arch Pathol Lab Med; 2021 Jan; 145(1):39-45. PubMed ID: 32966561
[TBL] [Abstract][Full Text] [Related]
37. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
Front Immunol; 2022; 13():911339. PubMed ID: 35711444
[TBL] [Abstract][Full Text] [Related]
38. Secondary organizing pneumonia after recovery of mild COVID-19 infection.
Golbets E; Kaplan A; Shafat T; Yagel Y; Jotkowitz A; Awesat J; Barski L
J Med Virol; 2022 Jan; 94(1):417-423. PubMed ID: 34581458
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.
Woo PC; Lau SK; Wong BH; Chan KH; Chu CM; Tsoi HW; Huang Y; Peiris JS; Yuen KY
Clin Diagn Lab Immunol; 2004 Jul; 11(4):665-8. PubMed ID: 15242938
[TBL] [Abstract][Full Text] [Related]
40. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
